Immunotherapies move beyond cancer, with first foray into sepsis
(By Asher Mullard for ST A T) D rug developers have tried for decades without success to develop treatments for
Read More
Part D/Prescription Drugs
Do I Still Need Medicare Part D?
In Kiplinger’s Ask Kim column, Kimberly Lankford answers the reader’s question on whether or not they need Medicare Part D
Read MoreSeniors Increasingly Getting High, Study Shows
(By Carmen Heredia Rodriguez for Kaiser Health News) Baby boomers are getting high in increasing numbers, reflecting growing acceptance of
Read MoreNovo Nordisk becomes second major drug maker to limit price hikes
(By Ed Silverman for ST A T) Y et another major drug maker is pledging to limit price hikes. Continue
Read MoreDon’t Miss This Deadline!
December 7 th is the deadline to switch from traditional Medicare to a Medicare Advantage plan effective for January 2017.
Read MoreMagic mushrooms drug shown to ease cancer patients’ depression
(By Bob Tedeschi for ST A T) he US medical community is slowly embracing marijuana. Will magic mushrooms be next?
Read MoreMylan CEO accepts full responsibility for EpiPen price hikes, but offers little explanation
(By Ed Silverman for ST A T) I n a rare appearance since the EpiPen controversy flared this summer, Mylan
Read MoreThe drug industry’s stake in Trumpcare is bigger than you think
(By Dylan Scott for ST A T) W ASHINGTON — The upcoming fight over repealing and replacing the Affordable Care
Read MoreDelivered ‘Like A Pizza’: Why Killer Drug Fentanyl Is So Hard To Stop
(By Martha Babanger, WBUR for Kaiser Health News) The latest chart of overdose deaths in Massachusetts shows a climbing blue
Read MoreTighter Prescribing Rules: An Anti-Abuse Strategy That Could Hurt Patients In Pain
(By Shefali Luthra for Kaiser Health News) As rates of prescription painkiller abuse remain stubbornly high, a number of states
Read More